Pfizer-BioNTech COVID-19 Vaccine May Get Approved By October
Pfizer and BioNTech last month took a $2 billion deal to supply an initial 100 million doses of the vaccine to the U.S.
Vaccine development for COVID-19 is going full-speed ahead whether it¡¯s the Oxford-AstraZeneca vaccine, the Moderna vaccine or even the Russian Sputnik V.
With every passing day we¡¯re getting closer to a cure to take down the novel coronavirus. And now, leading pharmaceutical giant Pfizer is catching up in this race.
Reuters
As per a report by Bloomberg, the vaccine being developed by Pfizer and BioNTech SE is currently on track to be submitted for regulatory review as early as October, after releasing additional data from an early-stage study.
As per the study, the vaccine worked well with mild to moderate fever in less than 20 percent of the participants. Researchers are still analysing data from Phase I trials in the US, and Germany, Pfizer & BioNTech said in a statement.
Representational image: Reuters
As per the report, this could make Pfizer¡¯s vaccine one of the fastest moving in the world. Some analysts also feel the vaccine could be approved for use as soon as November of this year. It is also crucial to note that Pfizer and BioNTech last month took a $2 billion deal to supply an initial 100 million doses of the vaccine to the U.S.
Taking vaccine to final stage with fewest side effects
The vaccine that Pfizer and BioNTech are working on is essentially a single nucleoside-modified messenger RNA (modRNA) based vaccine dubbed BNT162. The COVID-19 vaccine is essentially similar in tech as the Moderna vaccine that is as of now conducting its Phase III human trials.
Representational Image: Reuters
As per a report by AP, Pfizer and BioNTech are working to take the vaccine to the final phase of testing with the fewest side effects possible. According to a report released yesterday, Pfizer researchers looked at data from early-stage testing of two vaccine candidates. The vaccine showed better immune systems without any severe side effects.
However, one candidate showed fewer injection reactions that are often seen in older adults like fever, headache, chills etc, which are temporary but unpleasant. Pfizer has already commenced final testing of its lead candidate while it is looking to recruit 30,000 individuals in the US for testing.
